首页|Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
Non-alcoholic fatty liver disease (NAFLD) and diabetes mel-litus type 2 commonly coexist as a manifestation of meta-bolic syndrome. The presence of diabetes promotes the pro-gression of simple fatty liver to non-alcoholic steatohepatitis (NASH) and cirrhosis, and the presence of NAFLD increases the risk of diabetic complications. This coexistence affects a large part of the population, imposing a great burden on health care systems worldwide. Apart from diet modification and exercise, recent advances in the pharmacotherapy of diabetes offer new prospects regarding liver steatosis and steatohepatitis improvement, enriching the existing algo-rithm and supporting a multifaceted approach to diabetic patients with fatty liver disease. These agents mainly in-clude members of the families of glucagon-like peptide-1 analogues and the sodium-glucose co-transporter-2 inhibi-tors. In addition, agents acting on more than one receptor simultaneously are presently under study, in an attempt to further enhance our available options.
NAFLD/NASHDiabetes mellitus type 2SteatosisSGLT2GLP1
Emmanouil S.Koullias、John Koskinas
展开 >
nd Department of Internal Medicine,National and Kapodistrian University of Athens,Hippokration General Hospital,Ath-ens,Greece
NETL
NSTL
万方数据
维普
